Literature DB >> 1384898

Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting.

T Teshima1, M Harada, Y Takamatsu, K Makino, S Taniguchi, S Inaba, S Kondo, T Tanaka, K Akashi, I Minamishima.   

Abstract

We analysed 99 courses of leukapheresis after the use of cytotoxic drugs or cytotoxic drugs plus G-CSF (cytotoxic/G-CSF) to mobilize peripheral blood stem cells (PBSC) in 68 patients with hematologic or solid malignancies. Mean yields of granulocyte-macrophage progenitor cells (CFU-GM) with cytotoxic/G-CSF mobilization were significantly higher than those with cytotoxic mobilization (18.6 vs 8.40 x 10(4)/kg). The optimal timing of collection was different between these two mobilizations; the mean number of days to a peak level of circulating CFU-GM after cytotoxic/G-CSF mobilization was less than that after cytotoxic mobilization (24.2 vs 27.7 days). The leukocyte level on the day of peak CFU-GM was significantly higher in cytotoxic/G-CSF mobilization than that in cytotoxic mobilization (mean 12.8 vs 2.7 x 10(9)/l), whereas the platelet level was not different (mean 132 vs 125 x 10(9)/l). Increasing patient age was not a major adverse factor for PBSC collection. Synchronous recovery of both leukocytes and platelets was critical for achieving a high CFU-GM yield in these two mobilizations. Following PBSC autotransplantation, the rate of trilineage hematologic reconstitution showed a significant correlation with the infused dose of CFU-GM, whether they were collected with cytotoxic or cytotoxic/G-CSF mobilization. These results suggest that G-CSF can expand the PBSC pool and that CFU-GM yield after cytotoxic/G-CSF mobilization may predict trilineage hemopoietic reconstitution after ABSCT, as well as cytotoxic mobilization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384898

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  9 in total

1.  Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission.

Authors:  Jeeyun Lee; Mark H Lee; Keon Woo Park; Jung Hoon Kang; Do Hyung Im; Kihyun Kim; Se-Hoon Lee; Won Seog Kim; Jinny Park; Chul Won Jung; Keunchil Parka
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

2.  Storage of noncryopreserved periphered blood stem cells for transplantation.

Authors:  G Hechler; R Weide; J Heymanns; H Köppler; K Havemann
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

3.  Preserved in vivo reconstitution ability of PBSCs cryopreserved for a decade at -80 °C.

Authors:  T Shima; H Iwasaki; T Yamauchi; M Kadowaki; M Kiyosuke; T Mochimaru; K Takenaka; T Miyamoto; K Akashi; T Teshima
Journal:  Bone Marrow Transplant       Date:  2015-06-22       Impact factor: 5.483

4.  A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.

Authors:  Heather Renfroe; Mike Arnold; Louette Vaughn; R Donald Harvey; Ellie Hamilton; Sagar Lonial; H Jean Khoury; Jonathan L Kaufman; Mary Jo Lechowicz; Christopher R Flowers; Edmund K Waller
Journal:  Transfusion       Date:  2011-02-18       Impact factor: 3.157

Review 5.  Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.

Authors:  J E Frampton; Y E Yarker; K L Goa
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

6.  Virus reactivation in high-risk non-Hodgkin's lymphoma patients after autologous CD34+ -selected peripheral blood progenitor cell transplantation.

Authors:  Peng-Chan Lin; Ming-Yang Lee; Jen-Tsun Lin; Liang-Tsai Hsiao; Po-Min Chen; Tzeon-Jye Chiou
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

7.  Mobilization of Peripheral Blood Stem Cells Using Regimen Combining Docetaxel with Granulocyte Colony-stimulating Factor in Breast Cancer Patients.

Authors:  Jing Yu; Jun Ren; Li-Jun Di; Guo-Hong Song; Yu-Lin Zhu; Jie Zhang; Xu Liang; Li Che; Han-Fang Jiang; Jun Jia; Chun-Rong Zhang
Journal:  Chin J Cancer Res       Date:  2011-03       Impact factor: 5.087

8.  Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.

Authors:  P Dreger; P Marquardt; T Haferlach; S Jacobs; T Mülverstedt; V Eckstein; M Suttorp; H Löffler; W Müller-Ruchholtz; N Schmitz
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

9.  Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model.

Authors:  Justin B Callaway; Scott A Smith; Douglas G Widman; Karen P McKinnon; Frank Scholle; Gregory D Sempowski; Dirk P Dittmer; James E Crowe; Aravinda M de Silva; Jenny P-Y Ting
Journal:  PLoS One       Date:  2015-08-24       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.